Latest Anemia News
Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.
Management strategy also is associated with reduced mortality risk, but not achievement of hemoglobin targets.
End-stage renal disease is 32% more likely to develop in patients with C-reactive protein levels of 6.9 mg/L or higher vs 3.0 mg/L or lower.
Other risk factors include reduced muscle mass and lower levels of physical activity.
A recent study resulted in a new definition of less-than-optimal response to erythropoiesis-stimulating agents.
A hemoglobin level of 10.5 g/dL offers the optimal balance of cost and quality adjusted life years, researchers conclude.
The odds of developing anemia were 2-fold greater among patients with than without diabetes mellitus.
Anemia was associated with impaired activity levels at CKD stages 3, 4, and dialysis.
IV administration of vitamin B6 did not improve anemia or abnormal bone metabolism over 6 months.
Average weekly doses greater than 70 µg/week was associated with a 77% increased risk of cancer compared with no ESA exposure.
A high erythropoietin resistance index was associated with triple the risk for death from any cause.
Patients provided small doses of intravenous iron per treatment achieved higher hemoglobin levels than patients receiving weekly iron.
In a small study, 82% of patients had iron overload prior to hemodialysis initiation.
Less than half of anemic patients were prescribed ESAs or iron in the US and France, and a high percentage overall did not have iron indices measured.
Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.